Literature DB >> 21769120

Targeted therapies: Retargeting imatinib.

Rebecca Kirk.   

Abstract

Entities:  

Year:  2011        PMID： 21769120     DOI： 10.1038/nrclinonc.2011.105

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  2 in total

1.  Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial.

Authors:  Frédéric Millot; André Baruchel; Joelle Guilhot; Arnaud Petit; Thierry Leblanc; Yves Bertrand; Françoise Mazingue; Patrick Lutz; Cécile Vérité; Christian Berthou; Claire Galambrun; Frédéric Bernard; Karima Yacouben; Pierre Bordigoni; Christine Edan; Yves Reguerre; Gérard Couillault; Françoise Méchinaud; Jean-Michel Cayuela; François Guilhot
Journal:  J Clin Oncol       Date:  2011-06-13       Impact factor: 44.544

2.  Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.

Authors:  Jun Guo; Lu Si; Yan Kong; Keith T Flaherty; Xiaowei Xu; Yanyan Zhu; Christopher L Corless; Li Li; Haifu Li; Xinan Sheng; Chuanliang Cui; Zhihong Chi; Siming Li; Mei Han; Lili Mao; Xuede Lin; Nan Du; Xiaoshi Zhang; Junling Li; Baocheng Wang; Shukui Qin
Journal:  J Clin Oncol       Date:  2011-06-20       Impact factor: 44.544
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.